Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Malignancies.

Clinical pharmacology in drug development - 1 Jul 2020

Zhang Weijiang, McIntyre Christine, Riehl Todd, Forbes Harper, Bertran Enric, Choi Hye Jin, Lee Dae Ho, Lee Jeeyun

Abstract excerpt

This phase 1 open-label, multicenter, 3-period, fixed-sequence study evaluated the effect of multiple doses of vemurafenib on the pharmacokinetics of 1 dose of tizanidine, a probe CYP1A2 substrate, in patients with BRAFV600 mutation-positive metastatic malignancy. Patients received 1 dose of tizanidine 2 mg on day 1 (period A), vemurafenib 960 mg twice daily on days 2-21 (period B), and 1 dose of tizanidine 2 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyprus
Share to Cytochrome P-450 CYP1A2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Republic of Korea

Share to Vemurafenib

Source

Identifiers

PMID: 32311241
DOI: 10.1002/cpdd.788

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Malignancies.PMID 32311241Read ↗

Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies.Semantic proximity Read ↗

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.Semantic proximity Read ↗

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.Semantic proximity Read ↗

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.Semantic proximity Read ↗

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.Semantic proximity Read ↗

Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies.Semantic proximity Read ↗

Vemurafenib: a guide to its use in unresectable or metastatic melanoma.Semantic proximity Read ↗

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study.Semantic proximity Read ↗

Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.Semantic proximity Read ↗

Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.Semantic proximity Read ↗

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.Semantic proximity Read ↗

Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case reportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.